[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.147.69. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 473
Citations 0
News From the Food and Drug Administration
September 20, 2016

Injectable Diabetes Drug Approved

JAMA. 2016;316(11):1142. doi:10.1001/jama.2016.12431

A new medication that’s injected daily at mealtime has received FDA approval to help improve glycemic control, along with diet and exercise, in adults with type 2 diabetes.

Lixisenatide, marketed as Adlyxin, is a glucagon-like peptide-1 receptor agonist that increases glucose-dependent insulin release, decreases glucagon secretion, and slows gastric emptying. It will be available in a disposable, prefilled pen (http://bit.ly/2aP9yxj).

First Page Preview View Large
First page PDF preview
First page PDF preview
×